Outsourcing

Pharmaceutical Outsourcing Present and Future

Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Navigating the Preclinical CRO Outsourcing Process

The need for preclinical testing expertise is growing as molecular complexity increases.

A Closer Look at Affinity Ligands

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

Concept Life Sciences Opens New API Facility in UK

June 19, 2019

New CDMO facility supports early-stage API manufacturing and scale up.

Lonza Expands HPAPI Capacity

June 17, 2019

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

FUJIFILM Invests in New Continuous Processing Facility

June 07, 2019

The $10-million investment will include a 500-L single-use perfusion bioreactor and seven patented downstream processing units.

Tergus Pharma Plans Commercial Manufacturing Facility

June 07, 2019

Tergus Pharma announced a partnership with Great Point Partners and construction of a new commercial manufacturing facility in North Carolina.

iBio Launches Sterile Fill/Finish Services

June 05, 2019

CDMO iBio introduced cGMP sterile fill/finish services at its facility in Texas.

Filling the Early Intermediate Security Gap

June 02, 2019

With an increased focus on the supply chain security of non-cGMP intermediates, companies need to re-emphasize upstream manufacturing.

Batch or Continuous? Ask the Right Questions During Scale Up

June 02, 2019

Continuous manufacturing may offer huge opportunities, but it will not be right for every facility or product.

Catalent Announces OneBio Suite

May 28, 2019

New offering from Catalent targets integrated development and manufacturing of biologic drugs.

GE Healthcare, World Courier Announce Supply Chain Collaboration

May 28, 2019

By connecting manufacturing processes and logistics technology, GE Healthcare and World Courier look to accelerate the development of advanced therapies.

Particle Sciences Gains DEA Schedule I Registration

May 28, 2019

Expanded controlled substance capabilities enables Particle Sciences to develop and manufacture Schedule I–V drugs.